<DOC>
	<DOCNO>NCT00856700</DOCNO>
	<brief_summary>Glucagon-like peptide 1 ( GLP-1 ) intestinal peptide hormone secrete nutrient-dependent manner stimulate pancreatic beta cell secrete insulin response amount blood glucose . In patient Type 2 diabetes , GLP-1 secretion lower normal , thus suggest hormone may contribute pathogenesis disease . Whether infusion GLP-1 affect endothelial function glucose uptake human never investigate . In current proposal , investigator hypothesize GLP-1 administration might ameliorate endothelial dysfunction patient metabolic syndrome . To test hypothesis , investigator evaluate acute effect GLP-1 forearm circulation patient metabolic syndrome local hyperinsulinemia use forearm perfusion technique .</brief_summary>
	<brief_title>Glucagon-like Peptide 1 ( GLP-1 ) Endothelial Dysfunction Metabolic Syndrome</brief_title>
	<detailed_description>Subjects meet entrance criterion study quiet room temperature approximately 22Â°C . While participant supine , 20-gauge Teflon catheter insert brachial artery nondominant arm local anesthesia . This arm slightly elevate level heart , mercury-filled Silastic strain gauge place wide part forearm . The strain gauge connect plethysmography calibrate measure percent change volume ; plethysmograph turn connect chart recorder record forearm flow measurement . For measurement , cuff place upper arm inflate 40 mmHg rapid cuff inflator occlude venous outflow extremity . A wrist cuff inflate suprasystolic pressure l min measurement exclude hand circulation . Flow measurement record approximately 7 second every 15 second ; 7 reading obtain value . The intraarterial catheter connect 3-way stopcock pressure transducer ( measure intraarterial blood pressure ) infusion pump . Saline drug infused rate 0.5-1ml per minute . Another 20-gauge Teflon catheter insert homolateral antecubital vein blood sample . To assess effect GLP-1 insulin stimulate vasodilation , forearm instrument , patient metabolic syndrome receive intraarterial infusion saline 15 minute ; blood sample collect baseline flow measure . Then infusion regular insulin ( Humulin , Eli Lilly , Indianapolis , IN ; 0.1 mU per kg body weight per minute ) start . Next , forearm blood flow measure infusion Ach , vasodilator whose effect predominantly relate nitric oxide ( NO ) , sodium nitroprusside ( SNP ) , exogenous NO donor . After 20 min insulin infusion , another baseline measurement obtain continuous intraarterial infusion GLP-1 start 20 pmol/min infusion rate . This dose chosen order achieve intravascular GLP-1 concentration within infused forearm range ( approximately 0.50 pmol/mL ) previously show effective improve insulin sensitivity . GLP-1 infusion continue 60 minute , forearm blood flow measure every 30 minute ; venous blood sample obtain end infusion period . Then , maintain GLP-1 infusion unchanged , dose-response curve ACh SNP repeat , dose follow protocol .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>Otherwise healthy individual age 20 60 year Must satisfy 3 5 list criterion diagnosis metabolic syndrome ( ATP III ) include Pregnancy Liver disease Pulmonary disease Renal insufficiency Coronary heart disease Heart failure Peripheral vascular disease Coagulopathy Any disease predispose vasculitis Raynaud 's phenomenon Bleeding disorder Kidney stone Platelet count &lt; 150,000/ml blood Prothrombin time/partial thromboplastin time ( PT/PTT ) &gt; 1 second normal range , positive test HIV , hepatitis B C Subjects take kind medication include study ; therefore , antihypertensive and/or lipidlowering drug discontinue least 2 week enrollment study All subject tell refrain alcohol , beverage contain caffeine , smoke least 24 hour study perform</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>GLP-1</keyword>
	<keyword>Endothelial Function</keyword>
	<keyword>Metabolic Syndrome</keyword>
</DOC>